Sanger Institute study identifies genetic markers that predict blood cancer progression years early
This digest was compiled by AI from multiple sources — links to the originals are below.
A study by the Wellcome Sanger Institute identifies genetic markers that predict whether chronic blood cancers will progress years before symptoms appear. The findings, published in Cancer Discovery, could enable earlier intervention and help distinguish malignant conditions from benign age-related blood changes.
The Sanger Institute Study
Researchers from the Wellcome Sanger Institute and collaborators combined genetic analysis with detailed clinical records to track 30 patients with myeloproliferative neoplasms (MPNs). The study, published in Cancer Discovery and presented at the American Association of Cancer Research conference in San Diego, followed patients over several decades. MPNs affect about 40,000 people in the UK, with 4,000 new cases diagnosed annually. Most cases are linked to mutations in JAK2, CALR, or MPL genes, but 10% lack these common markers, complicating diagnosis.
Genetic Warning Signs
The team found major genetic differences between patients whose cancers remained stable and those whose disease eventually progressed to leukemia or myelofibrosis. In patients with progressive disease, specific DNA changes were detectable years before serious symptoms developed. For the 10% of patients lacking common MPN mutations, the genetic analysis helped confirm whether the blood changes were truly cancerous or simply age-related. The research indicates that chronic blood cancers carry detectable genetic signatures long before clinical deterioration, offering a window for early intervention.
Towards Earlier Diagnosis
The study suggests that routine genetic testing could distinguish between indolent MPNs and those likely to progress, potentially sparing some patients unnecessary chemotherapy. It also raises the possibility of developing screening programs for individuals with early genetic changes. However, the researchers caution that the findings are based on a small cohort of 30 patients and larger studies are needed to validate the markers. The work highlights the value of long-term patient tracking in understanding cancer evolution.
What's Next
The Wellcome Sanger Institute team plans to expand the study to a larger cohort to validate the predictive genetic markers. It remains unclear how quickly such genetic testing could be translated into standard clinical practice, given the need for regulatory approval and cost-effectiveness analyses.
1 source
Sanger Institute study identifies genetic markers that predict blood cancer progression years early
